These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 2975824)

  • 21. Hepatitis B vaccine: responder status and timing of additional booster doses.
    Fagan EA; Williams R; Eddleston AL
    Lancet; 1987 Sep; 2(8558):561. PubMed ID: 2887842
    [No Abstract]   [Full Text] [Related]  

  • 22. Should individuals with anti-HBs as the only marker of infection with hepatitis B receive hepatitis B vaccine?
    MacLeod JE; MacSween HM; Warner HA; Aterman K
    Can J Public Health; 1985; 76(4):229-32. PubMed ID: 2932209
    [No Abstract]   [Full Text] [Related]  

  • 23. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine.
    Weber DJ; Rutala WA; Samsa GP; Santimaw JE; Lemon SM
    JAMA; 1985 Dec; 254(22):3187-9. PubMed ID: 2933532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis B virus infection among Swedish adults: aspects on seroepidemiology, transmission, and vaccine response.
    Struve J
    Scand J Infect Dis Suppl; 1992; 82():1-57. PubMed ID: 1386474
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunogenicity and efficacy of anti-hepatitis B vaccines in hemodialysis patients.
    Dentico P; Volpe A; Buongiorno R; Maracchione N; Carbone M; Manno C; Proscia F
    Nephron; 1992; 61(3):324-5. PubMed ID: 1386904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations.
    Hollinger FB
    Am J Med; 1989 Sep; 87(3A):36S-40S. PubMed ID: 2528297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune response to a heat-inactivated hepatitis B vaccine in patients undergoing hemodialysis. Enhancement of the response by increasing the dose of hepatitis B surface antigen from 3 to 27 micrograms.
    Lelie PN; Reesink HW; de Jong-van Manen ST; Dees PJ; Reerink-Brongers EE
    Arch Intern Med; 1985 Feb; 145(2):305-9. PubMed ID: 3977491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose range study in healthy volunteers of a hepatitis B vaccine produced in yeast.
    Kuwert E; Scheiermann N; Gesemann M; Paar D; Safary A; Simoen E; Hauser P; Andre F
    Antiviral Res; 1985; Suppl 1():281-8. PubMed ID: 2935080
    [No Abstract]   [Full Text] [Related]  

  • 29. Is nonresponsiveness to hepatitis B vaccine due to latent hepatitis B virus infection?
    Luo KX; Wang LP; Nie J; Jiang S
    J Infect Dis; 1992 Apr; 165(4):777-8. PubMed ID: 1532408
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunogenicity, antibody persistence, and safety of the 60 μg hepatitis B vaccine in hemodialysis patients: a multicenter, randomized, double-blind, parallel-controlled trial.
    Feng Y; Shi X; Shi J; Gao L; Liu G; Cheng Y; Pan M; Li C; Wang J; Guo X; Zhang Y; Liang X; Wang S
    Expert Rev Vaccines; 2017 Oct; 16(10):1045-1052. PubMed ID: 28803502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Active pre-exposure immunisation against hepatitis B virus: immunogenicity of hepatitis B vaccine in healthy Thai adults and children.
    Pongpipat D; Suvatte V; Assateerawatts A; Bhethraratt S
    Asian Pac J Allergy Immunol; 1987 Jun; 5(1):63-5. PubMed ID: 2956961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prevalence of serum markers of hepatitis B virus in medical and non-medical personnel in a general hospital].
    Sánchez-Quijano A; Rivera F; Lissen E; Ollero M; Lozano F; García de Pesquera F; Vázquez R; Andreu-Kern F
    Med Clin (Barc); 1984 Jun; 83(1):1-3. PubMed ID: 6482541
    [No Abstract]   [Full Text] [Related]  

  • 33. Vaccine choice and program participation rates when two hepatitis B vaccines are offered.
    Harris AA; Daly-Gawenda D; Hudson EK
    J Occup Med; 1991 Jul; 33(7):804-7. PubMed ID: 1832443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Long-term immunogenicity of hepatitis B vaccine in the neonate and children at risk: antibody levels and indications for booster doses].
    Corbella E; Garghetti L; Poloniato A; Zambelloni C; Consonni A
    Minerva Pediatr; 1987 Oct; 39(20):821-6. PubMed ID: 2963953
    [No Abstract]   [Full Text] [Related]  

  • 35. Reversal by intradermal hepatitis B vaccination of unresponsiveness to HBsAg.
    Nagafuchi S; Kashiwagi S
    Lancet; 1987 Dec; 2(8574):1522-3. PubMed ID: 2892077
    [No Abstract]   [Full Text] [Related]  

  • 36. [Active preventive vaccination against hepatitis B].
    Jilg W
    Internist (Berl); 1985 Oct; 26(10):633-9. PubMed ID: 2934346
    [No Abstract]   [Full Text] [Related]  

  • 37. Hepatitis B vaccine.
    N Engl J Med; 1987 Jan; 316(1):47-9. PubMed ID: 2946954
    [No Abstract]   [Full Text] [Related]  

  • 38. Immune response to two different hepatitis B vaccines in haemodialysis patients: a 2-year follow-up.
    de Graeff PA; Dankert J; de Zeeuw D; Gips CH; van der Hem GK
    Nephron; 1985; 40(2):155-60. PubMed ID: 4000344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy.
    Dienstag JL; Werner BG; Polk BF; Snydman DR; Craven DE; Platt R; Crumpacker CS; Ouellet-Hellstrom R; Grady GF
    Ann Intern Med; 1984 Jul; 101(1):34-40. PubMed ID: 6233921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and side effects of low dose intradermally administered hepatitis B vaccine.
    Pathak UN; Dilawari JB; Chawla Y; Sokhey CS; Sharma BK; Ganguly NK
    Indian J Gastroenterol; 1988 Apr; 7(2):113-4. PubMed ID: 2966113
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.